Protocol Ledger

NCT04246489 · Phase II · COMPLETED

Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer

Interventional Phase II clinical trial protocol NCT04246489 sponsored by EMD Serono / Merck KGaA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-30 Enrollment: 146 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04246489
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)146 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04246489
Protocol FieldVerified Registry Value
NCT IdentifierNCT04246489
Consolidated Lead SponsorEMD Serono / Merck KGaA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment146 participants (ACTUAL)
Registered Start Date2020-03-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI